Mitophagy Effects of Protodioscin on Human Osteosarcoma Cells by Inhibition of p38MAPK Targeting NIX/LC3 Axis

Protodioscin (PD) is a steroidal saponin with various pharmacological activities, including neuro-protective, anti-inflammatory, and anti-tumor activities. However, the effect of PD on human osteosarcoma (OS) cells is unclear. In this study, we found that PD significantly inhibits the growth of human HOS and 143B OS cells through the upregulation of apoptotic-related proteins (cleaved caspase-3, cleaved caspase-9, and cleaved PARP) and mitophagy-related proteins (LC3B and NIX), which contribute to the induction of apoptosis, and MMP (mitochondrial membrane potential) dysfunction and mitophagy. The inhibition of LC3 or NIX was shown to decrease apoptosis and mitophagy in PD-treated OS cells. The knockdown of p38MAPK by siRNA decreased mitochondrial dysfunction, autophagy, mitophagy, and the NIX/LC3B expression in the PD-treated OS cells. A binding affinity analysis revealed that the smaller the KD value (-7.6 Kcal/mol and -8.9 Kcal/mol, respectively), the greater the binding affinity in the PD-NIX and PD-LC3 complexes. These findings show the inhibitory effects of PD-induced mitophagy in human OS cells and may represent a novel therapeutic strategy for human OS, by targeting the NIX/LC3 pathways.

Automated summary

In this study, PD was found to inhibit the growth of human OS cells by upregulating apoptotic-related proteins and mitophagy-related proteins. The inhibition of LC3 or NIX decreased apoptosis and mitophagy in PD-treated cells. Knockdown of p38MAPK decreased mitochondrial dysfunction, autophagy, mitophagy, and NIX/LC3B expression in PD-treated cells. Binding affinity analysis revealed a strong binding affinity in the PD-NIX and PD-LC3 complexes. These findings suggest that PD-induced mitophagy inhibition may represent a novel therapeutic strategy for human OS by targeting the NIX/LC3 pathways.